Trinity Biotech (TRIB) PT Lowered to $20 at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Trinity Biotech Announces Quarter 2 Financial Results Enrolment for the Meritas Troponin ACS Study Now Completed
July 28, 2015 9:29 AM EDTDUBLIN, July 28, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2015.
Quarter 2 Results                                                                                          Total revenues for Q2, 2015 were $24.3m compared to $26.0m in Q2, 2014. However, when the impact of foreign exchange movements, due to the strength of the US dollar against a range of other currencies, is removed, revenues would have been $25.4m this quarter, thus representing a decrease of 2%.Â
Point-of-Care revenues for Q2, 2015 were $3.4m, which represents a decrease of... More
